Tumor Microenvironment and Immunotherapy
Description
Our research group is strongly focused on clinical application. The group conducts translational studies using a reverse design approach, aiming to develop new biomarkers and rational, personalized therapeutic strategies for lung cancer patients.
PRIORITY RESEARCH LINES:
-
Discover and validate new mechanisms of sensitivity and resistance to immunotherapy and targeted therapies in lung cancer.
-
Identify new therapeutic targets for lung cancer patients.
-
Develop robust and clinically scalable predictive biomarkers.
-
Design and conduct early-phase (Phase I–II) and late-phase (Phase III) clinical trials with novel immunotherapies and targeted therapies for lung cancer patients.